Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 04, 2024

Efficacy and Safety of Temozolomide Given Every Other Week as a Second-Line Treatment for Advanced Neuroendocrine Carcinomas

ESMO Open

 

Additional Info

ESMO Open
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
ESMO Open 2024 Apr 13;9(5)103003, C von Arx, G Della Vittoria Scarpati, L Cannella, O Clemente, AL Marretta, A Bracigliano, F Picozzi, D Iervolino, V Granata, R Modica, A Bianco, C Mocerino, A Di Mauro, A Pizzolorusso, A Di Sarno, A Ottaiano, S Tafuto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading